While blockade of CCL20-CCR6 interactions has been shown to decrease colorectal tumor growth in a xenograft model [28] and administration of exogenous CCL20 has been shown to promote growth of syngeneic transplanted colorectal tumors [34], to our knowledge the effect of blockade of CCL20-CCR6 interactions on intestinal carcinogenesis in vivo in the setting of an intact host immune system has not been reported. The gene discussed is CCR6; the disease is colorectal neoplasm.